by Mrudula Kulkarni
3 minutes
Colleen Dixon Named CEO, Promises Bold Changes
Selkirk Pharma appoints Colleen Dixon as CEO, emphasizing strategic growth and operational excellence.
Selkirk Pharma, Inc., a leading U.S. pharmaceutical manufacturer specializing in injectable drugs and biological therapeutics, has appointed Colleen Dixon as its new Chief Executive Officer. Dixon, formerly the Vice President of Program Management at Selkirk Pharma, succeeds Patrick Haffey, who served as Chairman and CEO for the past six years.
Dixon's appointment marks a pivotal moment for Selkirk Pharma, underscoring its dedication to strategic expansion and operational excellence. With over three decades of experience in biopharma R&D and manufacturing leadership, Dixon brings a client-focused approach and profound industry knowledge to drive growth, enhance operations, and foster critical partnerships.
Prior to joining Selkirk Pharma, Dixon held key leadership positions at AstraZeneca, Baxter Biopharma Solutions, and Eli Lilly and Company, where she notably served as Head of Biopharmaceutical Project Management. Her extensive expertise in strategic planning, capital expansion, and organizational change management, coupled with direct manufacturing leadership in drug product and substance sectors, positions her to effectively guide Selkirk Pharma into its next phase of development.
Jim Bell, Chairman of the Board for Selkirk Pharma, “It is my distinct pleasure to welcome Colleen Dixon as the new Chief Executive Officer of Selkirk Pharma. With Colleen’s exceptional leadership skills, extensive industry experience, and visionary approach, we are confident that she will steer our company towards growth and success. Colleen's proven track record of innovation and commitment to excellence aligns perfectly with our strategic vision. We look forward to supporting her in this exciting new chapter for Selkirk."
Dixon said, “I am honoured to lead Selkirk Pharma into the next stage of its evolution. Our state-of-the-art facility, with its best-in-class labs and manufacturing technology, reflects the energy and dedication of our incredibly talented professionals. As we bring more capacity online to ensure a reliable supply of medications to patients, I am excited to drive our growth, foster innovation, and establish strong alliances that will benefit our stakeholders and customers in the aseptic fill/finish industry.”